Advertisement
Advertisement
Trending on Dermatology Times
1
Victoria Werth, MD, Discusses the Future of BDCA2 Inhibition in Cutaneous Lupus
2
Rezpegaldesleukin Shows Deepening Response and Long-Term Durability in 52-Week AD Trial
3
Christopher Bunick, MD, PhD, on Expanding Targets in Inflammatory Skin Disease
4
From Sidelines to Skin Care: The Dermatology Ads You May Have Missed From Super Bowl LX
5